Print

Purpose

The purpose of this study is to evaluate initial clinical safety, device functionality and effectiveness of the Edwards Transcatheter Atrial Shunt System.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Symptomatic Heart Failure (HF): - NYHA class II with a history of > II; III; or ambulatory IV AND - ≥ 1 HF hospital admission; or treatment with IV or oral diuresis within 12 months; OR an NT-pro BNP value > 150 pg./ml in normal sinus rhythm, > 450 pg./ml in atrial fibrillation, or a BNP value > 50 pg./ml in normal sinus rhythm, > 150 pg./ml in atrial fibrillation within the past 6 months prior to study entry. - On stable Guideline Directed Medical Therapy (GDMT) for heart failure - At rest: elevated LAP (or PCWP) of > 15 mmHg and LAP (or PCWP) exceeds right atrial pressure (RAP) by > 5 mmHg AND/OR supine ergometer exercise, elevated LA (or PCWP) pressure of > 25 mmHg and LA (or PCWP) exceeds right atrial pressure (RAP) by > 10 mmHg - Left Ventricular Ejection Fraction (LVEF) ≤ 40% - Pulmonary Vascular Resistance (PVR) < 4.0 WU

Exclusion Criteria

  • Severe HF: - Stage D, non-ambulatory NYHA Class IV, transplant list - If BMI < 30, Cardiac index < 2.0 L/min/m2 - If BMI ≥ 30, cardiac index < 1.8 L/min/m2 - Left Ventricular End-Diastolic Diameter (LVEDD) > 8 cm - LVEF < 20% - Valve disease: MR > 3+ or > moderate MS, TR > 2+, AR > 2+ or > moderate AS - MI or therapeutic invasive cardiac procedure < 3 months - TIA, stroke, CRT implanted < 6 months - RV dysfunction > mild by TTE OR TAPSE < 1.2 OR RV size ≥ LV size by TTE, OR right ventricular fractional area change (RVFAC) ≤ 25% - Dialysis OR renal dysfunction (S-CR > 2.5 mg/dl OR eGFR < 25 ml/min/1.73m2) - 6MWT < 50m OR > 600m - Active endocarditis or infection < 3 months - Mean Right Atrial Pressure (mRAP) > 15 mmHg at rest - Body Mass Index (BMI) ≥ 45 kg/m2

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Edwards Transcatheter Atrial Shunt System
  • Device: Transcatheter Atrial Shunt System
    Transcatheter treatment of symptomatic left heart failure patients

More Details

Status
Active, not recruiting
Sponsor
Edwards Lifesciences

Study Contact

Detailed Description

The early feasibility study of the Edwards Transcatheter Atrial Shunt System is a multi-center, prospective, early feasibility study to evaluate initial clinical safety, device functionality, and effectiveness of the Edwards Transcatheter Atrial Shunt System.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.